Clinical trials: Ophthalmological Disorder
Nasolacrimal Duct Obstruction
Immediate Office Probing vs Deferred Facility Probing for Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old
The purpose of this study is: To determine the cost-effectiveness of treating NLDO using immediate office probing compared with deferred probing in a facility setting.
- Trial name
- NLD3 (NCT00780741)
- Testing
- Immediate Office Probing, Deferred Facility Probing
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Jaeb Center for Health Research
Stroke, Neurologic Disorder
Evaluation of Bioness Integrated Therapy System (BITS) Touch Screen Technology to Improve Field Awareness
The Bioness Integrated Therapy System (BITS) (Bioness Inc. Valencia, CA) Touch Screen is an FDA approved device comprised of an interactive touchscreen and diverse program options to challenge patients through the use of visual…
- Conditions
- Stroke, Neurologic Disorder, Traumatic Brain Injury, Acquired Brain Injury
- Trial name
- NCT04930822
- Testing
- Table Top Visual Intervention, Bioness Integrated Therapy System Visual Intervention
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Gaylord Hospital, Inc
Astigmatism
Comparison of Senofilcon A Toric Lenses to Balafilcon A Toric Lenses Over Extended Wear Period
To evaluate two toric contact lenses on the ocular physiology of existing contact lens wearers when used in an extended wear modality of days/six nights.
- Trial name
- NCT00762502
- Testing
- senofilcon A toric contact lens, balafilcon A toric contact lens
- Where
- 8 sites in United States, Australia
- Volunteers
- 112 people
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Melanoma, Carcinoma, Non-Small- Cell Lung
A Study of SEA-CD40 Given With Other Drugs in Cancers
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial.
- Trial name
- NCT04993677
- Testing
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed
- Where
- 29 sites in United States, Canada and 4 more
- Volunteers
- 77 people
- Sponsor
- Seagen Inc.
Myopia
A Prospective, Contralateral, Eye to Eye Comparison of SMILE Surgery to LASIK Surgery
Subjects will undergo SMILE surgery in one eye and LASIK surgery in their other eye to correct myopia.
- Trial name
- NCT03067077
- Testing
- SMILE, LASIK
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Stanford University
Macular Degeneration
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
This is a Phase II multicenter, dose-ranging, randomized, active treatment (monthly ITV injection)-controlled study to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered through the Implant using three…
- Trial name
- LADDER (NCT02510794)
- Testing
- Ranibizumab
- Where
- 50 sites in United States
- Volunteers
- 225 people
- Sponsor
- Genentech, Inc.
Age-related Macular Degeneration
A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
This is a Phase III, multicenter, randomized, double-masked, dose-comparison study of the efficacy and safety of ranibizumab injection administered intravitreally to patients with choroidal neovascularization (CNV) secondary to…
- Trial name
- HARBOR (NCT00891735)
- Testing
- Ranibizumab
- Where
- 99 sites in United States
- Volunteers
- 1,097 people
- Sponsor
- Genentech, Inc.
Conjunctivitis, Allergic
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT01470118
- Testing
- alcaftadine 0.25% ophthalmic solution, olopatadine 0.2% ophthalmic solution, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Allergan
Uveitis, Cytoid Macular Edema
Lucentis for Inflammatory Macular Edema Trial
Uveitis is an inflammation (swelling and irritation) inside the eye, affecting the uvea. The uvea is the layer of the eye between the sclera and the retina and provides most of the blood supply to the retina.
- Trial name
- LIME (NCT00498355)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Homonymous Hemianopia
Clinical Trial of Peripheral Prism Glasses for Hemianopia
The purpose of this study is to evaluate the functional utility for general mobility (walking) of new high power permanent peripheral prism glasses, which provide visual field expansion device for patients with homonymous…
- Trial name
- NCT00494676
- Testing
- High power (57 prism diopter) peripheral prism glasses
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 73 people
- Sponsor
- Alexandra Bowers
Astigmatism, Myopia
Comparative Clinical Evaluation of Soft Toric Lens Designs
This study is evaluating the initial fit of toric contact lenses.
- Trial name
- NCT01552876
- Testing
- etafilcon A, nelfilcon A, Filcon II 3
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Astigmatism
Subjective Wearing Experience of the Total30 for Astigmatism Lens Among Satisfied Biofinity Toric Lens Wearers
To subjectively evaluate wearing experience in the T30fA lens among subjects who were already satisfied with their Biofinity Toric lenses.
- Trial name
- NCT05938010
- Testing
- Dailies Total1® contact lenses for astigmatism (T30fA)
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Scripps Poway Eyecare and Optometry
Dry Eye Syndromes
Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel
Objective: To assess the safety and tolerability of the PRO-165 formulation on the ocular surface of ophthalmologically and clinically healthy subjects.
- Trial name
- PRO-165 (NCT03697876)
- Testing
- PRO-165, Artelac
- Where
- Mexico
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Exfoliation Syndrome, Ocular Hypertension
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
Glaucoma is the world's the second leading cause of irreversible blindness. The World Health Organization (WHO) estimated the incidence of blindness due to glaucoma to be 4.4 million people worldwide in 2002.
- Conditions
- Exfoliation Syndrome, Ocular Hypertension, Open Angle Glaucoma
- Trial name
- ROCK (NCT01936389)
- Testing
- AR-12286
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Robert Ritch, MD, LLC.
Atopic Conjunctivitis
Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis
This study evaluates the efficacy and safety of Cyclosporine 0.010% eye drops in the treatment of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye).
- Trial name
- NCT00884585
- Testing
- Cyclosporine Vehicle, Cyclosporine 0.010%
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 176 people
- Sponsor
- Allergan
Macular Degeneration
Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
This study aims to evaluate the optimal use, efficacy, and safety of a Treat-and-Extend regimen with aflibercept in subjects with nAMD.
- Trial name
- ARIES (NCT02581891)
- Testing
- Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- 39 sites in Australia, Canada and 6 more
- Volunteers
- 287 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
- Conditions
- Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT06190093
- Testing
- bevacizumab, ranibizumab
- Where
- 61 sites in United States
- Volunteers
- 400 people
- Sponsor
- Outlook Therapeutics, Inc.
Amblyopia, Ocular Motility Disorders
A New Approach to Vision Therapy Based on Naturalistic 3-D Computer Gaming
The research team will execute two concurrent studies within a common framework. The first will compare iCare to standard of care occlusion therapy (patching) for amblyopia in patients ages 4 to 18 (inclusive).
- Trial name
- ICARE (NCT03066063)
- Testing
- iCare, Amblyopia standard of Care, CI standard of Care
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Barron Associates, Inc.
Allergic Conjunctivitis
A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Methodology Development Environmental Clinical Trial with Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic…
- Trial name
- NCT03660878
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Myopia
Side Effects of Atropine (SEA) Study
This study will perform several objective and subjective measurements of the eye and vision before and after a week of using 0.01% concentration atropine drops.
- Trial name
- SEA (NCT03593044)
- Testing
- 0.01% concentration atropine drops
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Jeffrey J. Walline, OD PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.